MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
